Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Lithium Americas Corp (LAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Lithium Americas Corp — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Lithium Americas Corp trades at $2.1 (market cap $800.75M). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 11.1× Lithium Americas Corp's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Lithium Americas Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Lithium Americas Corp for 27 Days on average.
| KYMR | LAC | |
|---|---|---|
Market Cap | $8.87B | $800.75M |
Volume | 779,107 | 6,634,849 |
Sector | Health | Basic Materials |
52-Week High | $127.31 | $9.44 |
52-Week Low | $55.80 | $2.07 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $8.26B | $1.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Lithium Americas (LAC) trades at $2.20, down 2.22% with bearish technical signals but positive analyst sentiment. The company shows negative profitability metrics with ROE at -9.56% and net income of -$122.09M for 2025, though it has beaten earnings expectations in recent quarters. Strong financing activity ($1.14B in 2025) supports Thacker Pass development, a key growth catalyst.
LAC presents a high-risk, high-reward opportunity with analyst consensus price target of $4.00 (82% upside). While current fundamentals are weak due to pre-revenue phase, successful execution at Thacker Pass could drive significant revaluation. Key risks include lithium price volatility, project execution challenges, and continued cash burn during development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →
